摘要目的 评估卵巢癌细胞减瘤术后腹腔热灌注化疗的临床疗效和安全性.方法 按制定的标准选取公开发表的文献,分别记录手术的种类和方法、腹腔热灌注化疗的方式、并发症、病死率、住院时间和生存时间等,并对化疗药物剂量、热灌注的方法、化疗持续时间等进行描述.结果 本荟萃分析最终有14篇符合标准的文献入选,7项研究表明进行了肿瘤根治术后腹腔热灌注化疗的患者预后较好.原发性卵巢癌和复发性卵巢癌患者治疗后的中位生存期为22个月到54个月；中位无病生存期为10个月到26个月.卵巢癌细胞减瘤术后腹腔热灌注化疗的严重并发症发生率为5％ ～ 36％；中位病死率3％(0％～10％),并发症发生率和病死率均较低.结论 卵巢癌患者细胞减瘤术后腹腔热灌注化疗是可以选择的一种良好的治疗方式,临床应用安全可行.

abstractsObjective To analyze the clinical efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy (HIPC) after cytoreductive surgery for ovarian carcinoma.Methods Based on the pre-designed criteria,the articles published were searched and recorded for data on types and options of surgery,use of HIPC,complications,mortalities,hospital stays and survival time.The dosage of chemotherapy agents,method of hyperthermic perfusion and duration of chemotherapy were also described.Results Fourteen articles were finally included in this meta-analysis.Among these,7 studies showed favorable patient outcomes with HIPC after radical tumor resection.The median survival time and median disease-free survival for primary ovarian carcinoma and relapsed ovarian carcinoma ranged from 22 to 54months and 10 to 26 months,respectively.The incidence of serious complications with HIPC after cytoreductive surgery ranged from 5％ to 36％,with the median mortality being 3％ (0％ -10％ ).The incidence of complications and the mortality were low.Conclusion HIPC after cytoreductive surgery may be used as a promising treatment which is clinically safe and feasible.